Salud financiera de hoja de balance de Salarius Pharmaceuticals

Salud financiera controles de criterios 3/6

Salarius Pharmaceuticals tiene un patrimonio de los accionistas total de $5.3M y una deuda total de $289.6K, lo que sitúa su ratio deuda-patrimonio en 5.5%. Sus activos y pasivos totales son $6.6M y $1.3M respectivamente.

Información clave

5.5%

Ratio deuda-patrimonio

US$289.64k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$5.90m
Patrimonio	US$5.29m
Total pasivo	US$1.30m
Activos totales	US$6.59m

Actualizaciones recientes sobre salud financiera

Recent updates

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Oct 14

Salarius adds 12% after updates on clinical programs and financials

Sep 13

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Aug 22

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Aug 08

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Aug 02

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Jun 07

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

May 27

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

Feb 09

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($6.5M) de SLRX superan a sus pasivos a corto plazo ($1.3M).

Pasivo a largo plazo: SLRX no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: SLRX tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de SLRX ha crecido de 0% a 5.5% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: SLRX tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: SLRX tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 30.9% cada año

Salud financiera de hoja de balance de Salarius Pharmaceuticals

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

Recent updates

Nasdaq Grants an Additional 180-Day Grace Period to Salarius Pharmaceuticals to Regain Compliance

Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Receives Notice from Nasdaq Stock Market

Insufficient new directors

Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals, Inc. announced that it has received $6.000001 million in funding

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Presents Sp-3164 Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. to Present SP-3164 Targeted Protein Degrader Preclinical Data At the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals, Inc. Announces Investigators Present Clinical Data on Its Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. Reports Impairment of Goodwill for the Three Months Ended September 30, 2022

Salarius Pharmaceuticals Presents Favorable Preclinical Data on Sp-3164 At the 5Th Annual Targeted Protein Degradation Conference

Salarius Pharmaceuticals, Inc. Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius pharmaceuticals announces 1-for-25 reverse stock split

Salarius adds 12% after updates on clinical programs and financials

Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers

Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01

Salarius Pharmaceuticals, Inc. Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for Ongoing Trial of Seclidemstat as A Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement

Salarius Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

Salarius Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Salarius Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX) acquired certain assets of DeuteRx, including DRX-164 for approximately $220 million.

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.069 loss per share (vs US$0.13 loss in 2Q 2020)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’S Safety, Dosing, and Drug Activity At American Society of Clinical Oncology (Asco) 2021 Annual Meeting

Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21

Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow

Price target decreased to US$4.10

Salarius Pharmaceuticals, Inc. Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.22 loss in 1Q 2020)

Full year 2020 earnings released: US$0.50 loss per share (vs US$2.12 loss in FY 2019)

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $19.999999 million.

Salarius Pharmaceuticals, Inc. Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Salarius Pharmaceuticals, Inc. Completes Dose-Escalation Stage of Phase 1/2 Clinical Trial in Relapsed and Refractory Ewing Sarcoma Patients, Initiates Expansion Stage in Ewing and Ewing-Related Sarcoma Patients

Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain

New 90-day high: US$1.58

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

New 90-day high: US$1.35

Salarius Pharmaceuticals, Inc. Announces Developing Seclidemstat

Salarius Pharmaceuticals receives second installment of $1.7M in payments

Salarius Pharma raises $3.5M via warrant exercise

New 90-day high: US$1.08

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.096 loss per share

Salarius Pharmaceuticals EPS in-line, beats on revenue

New 90-day low: US$0.73

New 90-day low: US$0.80

New 90-day low - US$0.99

Earnings released

Salarius Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.353451 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera